Geoffrey von Maltzahn, PhD

Co-Founder and Chief Innovation Officer

“ ”
I’m motivated by big challenges. Thousands of years ago, agriculture likely enabled human civilization. Today, we need to re-invent it so that it’s better for our health, our climate, and the environment around us—and this needs to be done in a way that scales to meet the needs of the whole world. That’s what our science at Indigo is about.

Geoffrey von Maltzahn, PhD

Geoffrey is the Chief Innovation Officer for Indigo. He is also a Partner at Flagship Pioneering, where he focuses on inventing technologies and starting companies to address global challenges in nutrition, environmental sustainability, and medicine. He is a co-founder of Indigo, Seres Therapeutics, Axcella Health, Kaleido Biosciences, and others.

Geoffrey served as Chief Technology Officer at Seres Therapeutics, where he led the build-out of the Microbiome Therapeutics platform and the discovery of SER-109, the first clinically-validated Microbiome Therapeutic, and VP Product Discovery at Axcella, where he led discovery of two clinically-validated drug candidates.

Geoffrey has been named as an inventor on over 100 patents and applications and received more than 20 awards for invention, including the Lemelson-MIT student prize, given to the most innovative student at MIT. He was awarded a Ph.D. in Biomedical Engineering and Medical Physics from MIT; a M.S. in Bioengineering from the University of California, San Diego; and a S.B. in Chemical Engineering from MIT.

Back